For almost nine months, The Cooper Companies, Inc. (NASDAQ:COO) has been trying to sell its CooperSurgical unit. But on September 9, 2026, the company ended the strategic review it had launched in December 2025 and decided to keep the business. The reason is that the bids received were not in shareholders’ interest and reflected a valuation disconnect from temporary factors. The third-quarter miss alongside a cut outlook sent the stock cratering about 15% to a 52-week low near $51. At 18 times earnings and down roughly 40% from its high, the question is whether this aborted sale represents seller capitulation or the market’s definitive judgment.
The Failed Auction Is a Rorschach Test
Management stated that acquisition offers undervalued the business due to temporary challenges including a new competitor in the non-hormonal IUD space and recent fertility litigation expenses. To signal conviction, the board authorized a new $1 billion share repurchase program. Bank of America, on the other hand, highlighted that a nine-month auction that ends with no deal indicates the buyers’ unwillingness to meet management’s valuation. This leaves the existing shareholders exposed to operational headwinds and lower forward guidance.
The Bigger Problem Isn’t CooperSurgical
The failed sale diverts the attention from the real problem: performance at CooperVision – the company’s core contact lens business. The business posted flat organic revenue growth in the third quarter. Meanwhile, the company initiated a reduction of U.S. channel inventory to establish a healthier normalized foundation ahead of fiscal 2027. The simultaneous slowdown in surgical assets and lens revenue triggered the guidance cut, which in turn pressures the premium multiple.
But the Washout Has Support
The bullish counterpoint is that CooperVision’s flatness is deliberate and not one created from lack of demand in the market. Additionally, free cash flow for the third quarter has hit a record $273 million, expanding the company’s financial flexibility. Institutional interest showed a modest increase prior to the announcement, with the Insider Monkey database recording 52 hedge funds holding COO in the second quarter of 2026 compared to 49 in the first quarter. Short interest stands at approximately 5.3% of the float.
Bottom Line
The failed sale matters less than it appears. CooperVision’s channel reset is the real tell. The lens franchise is the bulk of the value, and its 2027 reacceleration decides the real value of The Cooper Companies, Inc.. If distributor destocking concludes smoothly and surgical pressures abate, then the stock, with its near 52-week low, the record free cash flow, and the $1 billion buyback, supports accumulation. However, if organic lens growth remains sluggish, the multiple will compress further. Monitor distributor inventory normalization and lens organic sales in upcoming quarters before adding to positions.
READ NEXT: Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question and GE Aerospace (GE) Is Paying $12 Billion to Fix Its Biggest Bottleneck. Is It Worth It?
Hedge Fund Resource Center